Alicia L. Cooper, MPH, PhD; Lewis E. Kazis, ScD; David D. Dore, PharmD, PhD; Vincent Mor, PhD; Amal N. Trivedi, MD, MPH
Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government.
Grant Support: By the Health Assessment Lab (Alvin R. Tarlov & John E. Ware Jr. Doctoral Dissertation Award in Patient Reported Outcomes) and the National Institute on Aging (5RC1AG036158).
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2961.
Reproducible Research Statement: Study protocol and statistical code: Available from Dr. Cooper (e-mail, firstname.lastname@example.org). Data set: Not available.
Requests for Single Reprints: Amal N. Trivedi, MD, MPH, Department of Health Services, Policy and Practice, Brown University, Box G-S121-6, Providence, RI 02912; e-mail, email@example.com.
Current Author Addresses: Dr. Cooper: Department of Vermont Health Access, 312 Hurricane Street, Suite 201, Williston, VT 05495.
Dr. Kazis: Department of Health Policy and Management, Boston University School of Public Health (T-3W), 715 Albany Street, Talbot Building, Boston, MA 02118.
Dr. Dore: Department of Health Services, Policy and Practice, Department of Epidemiology, Brown University, Box G-S121-7, Providence, RI 02912.
Dr. Mor: Department of Health Services, Policy and Practice, Brown University, Box G-S121-7, Providence, RI 02912.
Dr. Trivedi: Department of Health Services, Policy and Practice, Brown University, Box G-S121-6, Providence, RI 02912.
Author Contributions: Conception and design: A.L. Cooper, L.E. Kazis, V. Mor, A.N. Trivedi.
Analysis and interpretation of the data: A.L. Cooper, L.E. Kazis, D.D. Dore, V. Mor, A.N. Trivedi.
Drafting of the article: A.L. Cooper, A.N. Trivedi.
Critical revision of the article for important intellectual content: A.L. Cooper, L.E. Kazis, D.D. Dore, V. Mor, A.N. Trivedi.
Final approval of the article: A.L. Cooper, L.E. Kazis, D.D. Dore, V. Mor, A.N. Trivedi.
Statistical expertise: L.E. Kazis, D.D. Dore, V. Mor.
Obtaining of funding: A.L. Cooper, A.N. Trivedi.
Administrative, technical, or logistic support: V. Mor.
Cooper AL, Kazis LE, Dore DD, Mor V, Trivedi AN. Underreporting High-Risk Prescribing Among Medicare Advantage Plans: A Cross-sectional Analysis. Ann Intern Med. 2013;159:456-462. doi: 10.7326/0003-4819-159-7-201310010-00005
Download citation file:
Published: Ann Intern Med. 2013;159(7):456-462.
Although Medicare Advantage plans are required to report clinical performance using Healthcare Effectiveness Data and Information Set (HEDIS) quality indicators, the accuracy of plan-reported performance rates is unknown.
To compare calculated and reported rates of high-risk prescribing among Medicare Advantage plans.
172 Medicare Advantage plans.
A random sample of beneficiaries in 172 Medicare Advantage plans in 2006 (n = 177 227) and 2007 (n = 173 655).
Plan-reported HEDIS rates of high-risk prescribing among elderly persons were compared with rates calculated from Medicare Advantage plans’ Part D claims by using the same measure specifications and source population.
The mean rate of high-risk prescribing derived from Part D claims was 26.9% (95% CI, 25.9% to 28.0%), whereas the mean plan-reported rate was 21.1% (CI, 20.0% to 22.3%). Approximately 95% of plans underreported rates of high-risk prescribing relative to calculated rates derived from Part D claims. The differences in the calculated and reported rates negatively affected quality rankings for the plans that most accurately reported rates. For example, the 9 plans that reported rates of high-risk prescribing within 1 percentage point of calculated rates were ranked 43.4 positions lower when reported rates were used instead of calculated rates. Among 103 680 individuals present in both the sample of Part D claims and HEDIS data in 2006, Medicare Advantage plans incorrectly excluded 10.3% as ineligible for the HEDIS high-risk prescribing measure. Among those correctly included in the high-risk prescribing denominator, the reported rate of high-risk prescribing was 21.9% and the calculated rate was 26.2%.
A single quality measure was assessed.
Medicare Advantage plans underreport rates of high-risk prescribing, suggesting a role for routine audits to ensure the validity of publicly reported quality measures.
Health Assessment Lab and National Institute on Aging.
Learn more about subscription options.
Register Now for a free account.
Healthcare Delivery and Policy.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only